Immix Biopharma, Inc. IMMX Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Immix Biopharma, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s return on assets?
- Immix Biopharma, Inc. (IMMX) reported return on assets of -60.4% in Q1 2026.
- How has Immix Biopharma, Inc.'s return on assets changed year-over-year?
- Immix Biopharma, Inc.'s return on assets increased by 21.6% year-over-year, from -77.1% to -60.4%.
- What is the long-term trend for Immix Biopharma, Inc.'s return on assets?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s return on assets has grown at a -35.2% compound annual growth rate (CAGR), from -260.3% to -46%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.